Literature DB >> 33244738

Association Between Neoadjuvant Chemoradiotherapy and Intractable Serous Ascites After Pancreaticoduodenectomy for Pancreatic Cancer.

Atsushi Tomioka1, Tetsunosuke Shimizu2, Shuji Kagota2, Kohei Taniguchi2, Koji Komeda2, Mitsuhiro Asakuma2, Fumitoshi Hirokawa2, Kazuhisa Uchiyama2.   

Abstract

BACKGROUND: Intractable serous (not chylous) ascites (IA) that infrequently develops early following pancreaticoduodenectomy (PD) for pancreatic cancer is a life-threatening problem. The relationship between neoadjuvant chemoradiotherapy (NACRT) for pancreatic cancer and the incidence of IA following PD has not been evaluated. This study aims to identify the risk factors associated with IA that develops early after PD for pancreatic cancer.
METHODS: We retrospectively identified 94 patients who underwent PD for pancreatic cancer at the Department of General and Gastroenterological Surgery, Osaka Medical College Hospital, Osaka, Japan, from April 2012 to March 2020. Data on 29 parameters were obtained from medical records. Univariate and multivariate analyses were conducted to identify independent risk factors. Levels of serum albumin were compared before and after NACRT to analyze its effect. Survival analysis was also conducted.
RESULTS: Of the 92 patients included in this study, 8 (8.70%) were categorized into the IA group. Multivariate analysis identified NACRT [odds ratio (OR) 27, 95% confidence interval (CI) 1.87-394, p = 0.016)] and hypoalbuminemia (≤ 1.6 g/dl) just after the operation (OR 50, 95% CI 1.68-1516, p = 0.024) as risk factors. The level of serum albumin was significantly decreased following NACRT. The IA group had poorer prognosis than the control group.
CONCLUSIONS: IA is a serious problem that aggravates patient's prognosis. Postoperative lymphatic leak might be a trigger of IA. NACRT was a major risk factor, followed by hypoalbuminemia caused by various reasons. These factors may act synergistically and cause IA.

Entities:  

Year:  2020        PMID: 33244738     DOI: 10.1245/s10434-020-09401-w

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Incidence and risk factors of chylous ascites after pancreatic resection.

Authors:  Wu Pan; Chen Yang; Shen-Yang Cai; Zhi-Meng Chen; Nan-Sheng Cheng; Fu-Yu Li; Xian-Ze Xiong
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  In vitro effects of 0 to 120 Grays of irradiation on bone viability and release of growth factors.

Authors:  Kosaku Sawada; Masako Fujioka-Kobayashi; Eizaburo Kobayashi; Jens O Brömme; Benoit Schaller; Richard J Miron
Journal:  BMC Oral Health       Date:  2016-07-04       Impact factor: 2.757

3.  Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer.

Authors:  David Wittmann; William A Hall; Kathleen K Christians; Chad A Barnes; Neil R Jariwalla; Mohammed Aldakkak; Callisia N Clarke; Ben George; Paul S Ritch; Matthew Riese; Abdul H Khan; Naveen Kulkarni; John Evans; Beth A Erickson; Douglas B Evans; Susan Tsai
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 6.244

Review 4.  Wound healing after radiation therapy: review of the literature.

Authors:  Frank Haubner; Elisabeth Ohmann; Fabian Pohl; Jürgen Strutz; Holger G Gassner
Journal:  Radiat Oncol       Date:  2012-09-24       Impact factor: 3.481

  4 in total
  2 in total

1.  Tumor Necrosis in Hepatocellular Carcinoma-Unfairly Overlooked?

Authors:  Lana Bijelic; Emilio Ramos Rubio
Journal:  Ann Surg Oncol       Date:  2020-11-22       Impact factor: 5.344

2.  A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study.

Authors:  Huaqing Shi; Zhou Chen; Shi Dong; Ru He; Yan Du; Zishun Qin; Wence Zhou
Journal:  BMC Gastroenterol       Date:  2022-06-03       Impact factor: 2.847

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.